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Abstract
Listeriosis is a resurgent foodborne disease in European countries. Benefits of combined b-lactam-aminoglycoside treatment remain con-
troversial and the impact of the underlying disease on prognosis has not been fully assessed. We conducted a retrospective review of
cases of sporadic listeriosis in adults from 1995 to 2008 at two university-affiliated hospitals serving a population of 600 000 people in
Madrid, Spain. The primary end-point was the associated in-hospital mortality. Sixty-four patients were studied. Estimated incidence of
listeriosis was 0.76/100.000 persons/year. Seventy-four per cent had chronic underlying diseases; cirrhosis of the liver and haematologi-
cal and solid neoplasias were the most common comorbidities. Primary bacteraemia (58%) and meningitis (42%) were the most frequent
manifestations. Focal infections were seen in ten cases. In-hospital mortality was 31%. Patients treated with ampicillin or with an ampicil-
lin-gentamicin combination did not differ in age, severity of underlying disease or type of presentation. Differences in mortality were
not seen between patients treated with monotherapy and those given combined treatment (28% vs 35%; p 0.634). Ten patients were
treated with trimethoprim-sulfamethozaxole alone and only one died. All patients without comorbidities survived infection but mortality
of patients with cirrhosis of the liver was 21% and that of patients with haematological or solid neoplasias was 66%. Only haematological
neoplasia (OR 6.67; 95% CI 1.71–26.04; p 0.006) was significantly associated with an increased risk of mortality (R2Cox–Snell = 0.262).
Mortality of listeriosis mainly depended on the severity of the underlying disease. Combined ampicillin-gentamicin therapy did not
improved survival. Trimethoprim-sulfamethozaxole may be an effective alternative therapy for listerial infections.
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Introduction
Listeriosis is a resurgent foodborne disease caused by the
bacterium Listeria monocytogenes. It has been estimated that
1850 cases occur annually in the USA [1]. In Western Eur-
ope the incidence of listeriosis has ranged from 0.3 to 0.8/
100 000 persons/year in France and Italy respectively,
although it seems to be increasing in the UK and other
countries [2–5].
Listeria monocytogenes is found in soil, silage, water and a
variety of raw foods such as meats or vegetables, and in pro-
cessed foods such as soft cheeses and cold cuts [1,4]. It pro-
duces a severe disease characterized by septicaemia and
meningitis with mortality rates from 20 to 50% [6]. Pregnant
women can transmit the infection to the fetus, for whom
the result can be fatal.
Several high-risk conditions for listeriosis have been identi-
fied. Malignancies, kidney disease and renal transplant, diabe-
tes, alcoholism, increased age, liver disease and connective
tissue disorders are the main predisposing factors [1,5]. In
addition, patients with AIDS and those on treatment with
tumour necrosis factor-a inhibitors also have an increased
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risk of listeriosis [7,8]. The susceptibility of healthy persons
is substantially less than that of persons with underlying con-
ditions. This predisposition is a consequence of suppressed
T-cell-mediated immunity caused by the condition or its
treatment [1].
Recommendations regarding therapy are based on data
from in vitro tests, animal models and clinical experience.
Penicillin and ampicillin are the preferred agents but because
of delayed bactericidal activity against Listeria, most experts
suggest adding gentamicin to ampicillin for the treatment of
listeriosis [1,9]. Nonetheless, the benefits of combined treat-
ment remain controversial and the effect of the underlying
disease on prognosis may be of paramount importance.
The objectives of this investigation were to determine the
incidence of listeriosis in adults in a metropolitan area of
Madrid, and to assess the effect on mortality of adding genta-
micin to b-lactam therapy. Because the severity of the under-
lying disease may be of even greater prognostic importance,
an analysis of risk factors of mortality was also performed.
Patients and Methods
We conducted a retrospective review of a cohort of consec-
utive cases of sporadic listeriosis in adult patients from 1995
to 2008 at two university-affiliated hospitals serving a popula-
tion of 600 000 people in Madrid.
Diagnosis was based on the isolation of L. monocytogenes
from blood or cerebrospinal fluid. Bacterial identification was
done following conventional methods [10]. Gram-positive,
non-spore-forming rod, facultative anaerobes, that produced
catalase and a narrow haemolysis and tumbling at 20–25C
were presumptively identified as Listeria. Further identifica-
tion was by means of biochemical tests using API-Coryne;
(BioMerieux, Marcy l’Etoile France). Susceptibility tests were
performed following the CLSI recommendations [11].
Diagnosis of central nervous system infection was estab-
lished on clinical grounds, cerebrospinal fluid analysis and
when indicated by neuroimaging.
Listeriosis was considered hospital-acquired when signs
of infection and isolation of Listeria occurred ‡72 h after
admission.
Full daily doses of ampicillin (12 g) for adult patients with
normal renal function were used. Gentamicin was used at
doses of 1.5 mg/kg/8 h. For both antibiotics, dosage adjust-
ments were made in patients with renal dysfunction.
The main measurement was the associated in-hospital
mortality defined as death occurring before day 21 of hospi-
talization in association with listeriosis (septic shock, persist-
ing sepsis, multi-organ dysfunction, brain damage). Deaths
related to the underlying condition (e.g. progression of
haematological neoplasia, gastrointestinal bleeding or hepatic
encephalopathy) were not considered associated with listerio-
sis and were not entered in the final analysis. Age over
65 years, gender, chronic debilitating disease, cirrhosis of the
liver, haematological neoplasia, solid neoplasia, immuno-
suppressive disease, bacteraemia, meningitis, ampicillin mono-
therapy and combined ampicillin-gentamicin were the
variables considered in the analysis of risk factors of mortality.
Statistics
SPSS 16.0 was used for the statistical analysis of the data.
Continuous variables were expressed as mean ± standard
difference. Discrete variables were expressed as percentages.
Association between qualitative variables was tested using
chi-squared tests or Fisher exact test when sample size was
small. Strength of association was measured by odds ratio
(OR) or Haldane’s estimator for small sample 2 · 2 tables
and their 95% CI. Differences between groups were consid-
ered significant at p <0.05.
Multivariate analysis was performed using a logistic regres-
sion model. The selection of variables for this multivariate
analysis was performed by a forward-conditional method, with
significance levels of £0.05 for inclusion and ‡0.1 for exclu-
sion. Cox–Snell R2 was used to assess the overall model fit.
Results
Sixty-four patients with sporadic invasive listeriosis were
assessed. The estimated incidence was 0.76/100.000 persons/
year. Patients had a mean age of 58.8 years, ranging from 19
to 86 years. Sixty-seven per cent were men.
Forty-seven (74%) had a chronic underlying disease. Cir-
rhosis of the liver (14 patients; 30%), other chronic disease
such a diabetes, alcoholism or chronic renal failure (ten
patients; 21%), haematological neoplasia (12 patients; 25%),
solid neoplasia (six patients; 13%), and a miscellaneous group
of immunocompromised hosts on high-dose corticosteroid
therapy (five patients; 11%) were the most common comor-
bidities. Seventeen patients (26%) were adults without pre-
disposing factors.
Listeriosis was acquired in the community in 47 instances
(73%) and was hospital-acquired in 17 (27%). Hospital out-
breaks were not observed and in cases in which listeriosis
developed during hospitalization we did not identify a food-
borne or other source of infection.
Primary bacteraemia (37 patients; 58%) and meningitis (27
patients; 42%) were the most common manifestations. Signs
of meningoencephalitis or rhombencephalitis were observed
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in seven (26%) patients with central nervous system listerio-
sis. Focal, extraneural infections were seen in ten cases
(16%): bacterial peritonitis in four, endocarditis in three and
brain abscess in another three. Table 1 shows some clinical
findings and outcome for these patients.
Table 2 lists the results of susceptibility tests of 46 isolates
of L. monocytogenes to 13 antimicrobials.
Twenty patients died as consequence of listeriosis (31%).
Most patients died in the first week of hospitalization from
septic shock and multiorgan dysfunction or brain damage in
association with listeriosis. Three of these patients who were
empirically treated with inappropriate third-generation ceph-
alosporins died during the first 48 h of admission in septic
shock. These patients were excluded from the analysis of
risk factors for mortality.
Patients were treated with ampicillin alone or in combina-
tion with gentamicin, or with trimethoprim-sulfamethoxazole.
Generally, ampicillin or ampicillin plus clavulanate were
started in combination with other antibiotics as part of an
empiric regimen for sepsis and meningitis. Antimicrobial
therapy was changed and other antimicrobials were stopped
when isolation of Listeria was reported. Trimethoprim-sulfa-
methoxazole was initial therapy in some patients with menin-
gitis in whom Gram stain of the cerebrospinal fluid showed
Gram-positive bacilli or was given within the first 24 h after
isolation of Gram-positive bacilli in blood cultures or cere-
brospinal fluid.
Table 3 shows the results of treatment of listeriosis in
adults. Patients treated with ampicillin alone or with ampicil-
lin plus gentamicin did not differ in age (36% and 43% above
65 years, respectively), gender, severity of underlying disease
or type of presentation. The number of patients without
comorbidities (25% vs 39%), haematological or solid-organ
cancer (25% vs 26%) and other chronic debilitating diseases
(46% vs 26%) were not significantly different between the
groups of patients. Differences in mortality were not seen
(28% vs 35%, respectively; p 0.634).
Ten patients were treated with only trimethoprim-sulfa-
methoxazole. Table 4 shows the most relevant clinical
findings observed in these individuals. Significant differences
in mortality were not recorded among patients treated with
ampicillin and trimethoprim-sulfamethoxazole (28% vs 10%,
respectively; p 0.396).
Mortality varied according to the underlying condition.
Whereas all patients without comorbidities survived infec-
tion, mortality of patients with haematological and solid neo-
plasias was 66% (eight out of 12 and four out of six,
respectively). Mortality in patients with cirrhosis and other
chronic debilitating diseases was 21.4% and 20%, respectively.
Haematological neoplasia (OR 14.4; p 0.001), solid neoplasia
(OR 14.4; p 0.007) and immunosuppressive disease (OR
10.8; p 0.021) were associated with mortality.
TABLE 1. Clinical findings and outcome of patients with focal, extra-meningeal infections caused by Listeria monocytogenes
Patient Age/sex Underlying condition/focal infection Manifestations Treatment Outcome
1 75/M Liver cirrhosis/primary bacterial peritonitis Fever, abdominal pain, diarrhoea A + G Cured
2 69/M Liver cirrhosis/primary bacterial peritonitis Fever, abdominal pain, hepatic encephalopathy A + G Cured
3 59/M Liver cirrhosis/primary bacterial peritonitis Fever, abdominal pain, hepato-renal syndrome A Died
4 62/M Liver cirrhosis/primary bacterial peritonitis Fever, abdominal pain, hepatic encephalopathy A Cured
5 60/M Liver cirrhosis/brain abscess. Fever, headache, hemiparesis TMP-SMZ Cured
6 36/M Non-Hodgkin’s lymphoma/brain abscess Fever, seizures, septic shock A Died
7 71/M Wegener granulomatosis/brain abscess Fever, seizures, confusion A + TMP-SMZ Cured
8 74/M Aortic prosthesis/PVE Fever, peripheral emboli A + G Cured
9 77/M Aortic prosthesis/PVE Fever, heart failure A + G + VR Cured
10 68/M Mitral prosthesis/PVE Fever, heart failure A + G + VR Cured
M, male; F, female; A, ampicillin; G, gentamicin; TMP-SMZ, trimethoprim-sulfamethoxazole; PVE, prosthetic valve endocarditis; VR, valve replacement.
TABLE 2. Susceptibility of Listeria monocytogenes to various
antimicrobials
Agent
Minimal inhibitory concentration mg/L
Range MIC50 MIC90
Benzylpenicillin 0.06–0.5 0.25 0.5
Erythromycin 0.12–0.25 0.12 0.25
Clarithromycin 0.12 0.12 0.12
Azithromycin 0.25–1 0.5 1
Doxycycline 0.06–0.25 0.12 0.25
Josamycin 1–4 2 2
Lincomycin 2–128 8 16
Vancomycin 0.25–1 1 1
Teicoplanin 0.2 5–0.5 0.25 0.5
Rifapentine 0.03–64 0.06 0.12
Quinupristin-dalfopristin 2–16 4 4
Levofloxacin 0.25–2 0.5 1
TMP-SMZ 0.06–0.5 0.5 0.5
46 strains tested.
TABLE 3. Results of the treatment of listeriosis with differ-
ent antimicrobials and combinations
Antimicrobials Treated, n Died, n /(%) Survived, n /(%)
Ampicillin alone 28 8 (28) 20 (72)
Ampicillin plus gentamicin 23 8 (35) 15 (65)
Trimethoprim-sulfamethoxazol 10 1 (10) 9 (90)
Other regimensa 3 3 (100)
No differences for comparisons of ampicillin alone vs ampicillin plus gentamicin
(p 0.634) or ampicillin vs TMP-SMZ (p 0.396).
aThird-generation cephalosporins.
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In the multivariate analysis, only haematological neoplasia
(OR 6.67; 95% CI: 1.71–26.04; p 0.006) was significantly
associated with an increased risk of mortality (R2Cox–Snell =
0.262). Age over 65 years (p 0.084), sex (p 0.802), chronic
debilitating disease (p 0.164), cirrhosis (p 0.519), haemato-
logical neoplasia (p 0.006), solid neoplasia (p 0.071), immuno-
suppressive disease (p 0.171), bacteraemia and meningitis
(p 0.394), ampicillin monotherapy (p 0.967) and combined
ampicillin-gentamicin (p 0.781) were not independent factors
for mortality.
Discussion
In recent years an increasing rate of listeriosis has been
reported in some European countries [3,5]. These increases
primarily reflect a higher rate of bacteraemic listeriosis in
the elderly, and are not otherwise correlated with geogra-
phy, socioeconomic status or serotypes [3]. However, in the
USA, non-perinatal listeriosis-associated deaths have
decreased, paralleling a decreasing trend in incidence [12].
From our investigation it seems clear that the incidence of
invasive listeriosis in Madrid was equivalent to that observed
in other European countries and parts of Spain [2,13].
There is compelling evidence that invasive listeriosis is
mainly a disease of people with a variety of chronic conditions
including severe immunosuppressive disorders [5,14]. Cirrho-
sis of the liver, diabetes mellitus, chronic renal failure, haema-
tological and solid-organ neoplasia, and treatment with
corticosteroids were the most common factors predisposing
for listeriosis. The absence of AIDS as a high-risk condition in
our study might reflect the generalized use of trimethoprim-
sulfamethoxazole in patients with severe CD4+ lymphocyte
depletion [7]. By the same token, trimethoprim-sulfamethox-
azole given for prophylaxis of Pneumocystis jirovecii infection,
has been reported to be an effective preventive therapy for
listeriosis in solid-organ transplant recipients [15].
Primary bacteraemia and meningoencephalitis were the
predominant manifestations of listeriosis [1,14,16]. Of inter-
est was the occurrence of focal, extracranial involvement by
Listeria in 16% of our cases, a percentage equivalent to that
observed by others [16]. Bacterial peritonitis in patients with
cirrhosis, and brain abscess and endocarditis in patients with
prosthetic valves were the most common infections
observed in this and other series [7,16].
Currently, listeriosis is frequently a nosocomial infection
and from 16% to 30% of cases are hospital-acquired [16,17].
Twenty-seven per cent of patients in this series developed
listeriosis during hospitalization for other diseases. Cases
occurred sporadically without temporal aggregation and we
did not find a hospital source of listeriosis in these patients.
All cases occurred within the first 2 weeks of hospitalization,
a short time that makes unlikely the nosocomial acquisition
of listeria, which may have an incubation period up to
1 month [18]. Because faecal asymptomatic carriage is not
uncommon [1,17], we suggest that colonization could have
occurred before hospitalization and infection then developed
after admission, favoured and triggered by increased
immunosuppression, antibiotic therapy, alkalinization of the
stomach by antiacids or some other circumstances.
Mortality from listeriosis remains high, ranging from 20%
to 38% in most recent series [14–17,19,20]. Nevertheless,
data on risk factors for mortality are limited. Guevara et al.
[14] found that non-haematological malignancy, alcoholism,
steroid medication, and kidney disease were risk factors for
mortality. Patients admitted to the hospital with a diagnosis
of sepsis alone had the highest mortality [14]. Others found
renal failure, corticosteroid therapy and hospital-acquired
infection associated with a poor prognosis [16]. Severe
immunosuppression and infection caused by serotype 4b
have also been implicated in fatal prognosis [21,22].
Age above 70 years has been considered an important risk
factor for mortality [14]. However, Gerner-Smidt et al. [22]
found that age was not a significant risk factor for mortality,
but was an effect modifier of the risk associated with under-
lying illness. Among patients aged below 70 years, a condi-
tion known to predispose to listeriosis was an important risk
factor for mortality but this was not the case for patients
TABLE 4. Summary of clinical find-
ings and outcome of patients with
invasive listeriosis treated with tri-
methoprim-sulfamethoxazole
Patient Age/sex Underlying disease Manifestation Outcome
1 31/M Non-Hodgkin lymphoma Bacteraemia Lived
2 29/F Acute leukaemia Bacteraemia Lived
3 70/M None Meningitis Lived
4 81/M Cirrhosis of the liver Bacteraemia Lived
5 60/M Cirrhosis of the liver Brain abscess Lived
6 68/M Diabetes mellitus, CRF Meningitis Lived
7 69/M Alcoholism, diabetes Bacteraemia Lived
8 68/F SLE, C&E treatment Bacteraemia Lived
9 50/F Cirrhosis of the liver Meningitis Lived
10 70/F Myelocytic leukaemia Meningitis Died
CRF, chronic renal failure; SLE, systemic lupus erythematosus; C&E, corticosteroid therapy.
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over 70 years, whose risk of mortality was independent of
other conditions [22]. In our series, age was not an indepen-
dent factor associated with mortality. Mortality from listerio-
sis seemed to depend most directly on the severity of the
underlying disease and haematological neoplasia was signifi-
cantly associated with an increased risk of death. As shown
by others, patients with solid-organ neoplasia and those who
were immunosuppressed as the result of corticosteroid ther-
apy also exhibited high rates of mortality [14,15,22]. This is
in sharp contrast with the favourable prognosis of listeriosis
in adults without predisposing conditions.
The effect of the kind of treatment on prognosis of liste-
riosis remains controversial. Because in vitro and in vivo
ampicillin monotherapy produces a suboptimal response,
combination of ampicillin with gentamicin has been the pre-
ferred treatment in clinical practice [1,9,19]. However, renal
failure is frequently found in patients with listeriosis and
those with cirrhosis or diabetes are prone to develop renal
failure during gentamicin therapy [16]. For these reasons, the
role of aminoglycoside in the treatment of listeriosis must be
re-evaluated.
Mitja et al. [16] found that among 102 patients with listeri-
osis, 32% were treated with ampicillin plus gentamicin and
68% received monotherapy with ampicillin. Both groups
were equivalent in terms of age, underlying disease, type of
presentation and other factors. Mortality was higher in
patients treated with the combination of ampicillin and am-
inoglycosides than in those with ampicillin monotherapy,
although the results did not reach significance. Hence, in this
investigation gentamicin did not decrease early mortality but
seemed to increase it [16]. Similarly in our study, we did not
find differences in mortality among patients with listeriosis
treated with ampicillin monotherapy and those given com-
bined treatment.
Susceptibility of L. monocytogenes to penicillins and other
antimicrobial agents has remained unchanged and most iso-
lates are susceptible to a wide variety of antimicrobials
[23,24]. The prevalence of resistant strains was estimated at
1.27% among clinical isolates [25].
Trimethoprim-sulfamethoxazole is bactericidal for Listeria
[23]. However, only a few cases of listeriosis treated with
trimethoprim-sulfamethoxazole have been reported so far
[26]. In patients with meningitis who had a rapid clinical
response to therapy, trimethoprim-sulfamethoxazole has
been successfully used to extend antimicrobial therapy in the
outpatient setting [27]. The combination of trimethoprim-sul-
famethoxazole plus ampicillin was associated with a much
lower failure rate and fewer neurological sequelae than ampi-
cillin combined with gentamicin [28]. In our experience, tri-
methoprim-sulfamethoxazole was effectively used in patients
with listeriosis and 90% of patients with bacteraemia and/or
meningitis were cured. Two patients with brain abscess were
treated with trimethoprim-sulfamethoxazole alone or com-
bined with high-dose ampicillin and both had an uneventful
recovery without neurological sequelae. We believe that
trimethoprim-sulfamethoxazole is a safe and useful alterna-
tive therapy for patients with invasive listeriosis. Trimetho-
prim-sulfamethoxazole has bactericidal extracellular and
intracellular activity against Listeria and excellent central ner-
vous system penetration, and so may be effective for the
treatment of refractory listeriosis.
Our study has some limitations. Basically, it is a retrospec-
tive study considering a relatively small number of cases seen
over a period of 14 years and some uncontrolled factors
could have confounded our results. The potential for differ-
ential care among these hospitalized patients is likely to be
minimal because all patients were seen by a small number of
healthcare providers with similar training and prescription
habits and who use the same diagnostic and therapeutic
tools. They can, therefore, be considered a homogeneous
group in this respect.
Our findings suggest that underlying conditions themselves
appear to be more important than the kind of treatment in
determining prognosis. The findings of this study should high-
light the importance of certain underlying conditions, particu-
larly haematological neoplasia, and their association with high
mortality rates. Because factors determining outcome seem
unchangeable, prevention must be reinforced.
The number and diversity of conditions that appear to
increase the risk and mortality of listeriosis imply that health-
care providers should consider listeriosis when treating
patients with concurrent conditions and provide appropriate
food safety advice [29].
Transparency Declaration
No conflicts of interest declared.
References
1. Lorber B. Listeriosis. Clin Infect Dis 1997; 24: 1–9.
2. de Valk H, Jacquet C, Goulet V. Surveillance of listeria infections in
Europe. Euro Surveill 2005; 10: 251–255.
3. Goulet V, Hedberg C, Le Monnier A, de Valk H. Increasing incidence
of listeriosis in France and other European countries. Emerg Infect Dis
2008; 14: 734–740.
4. Allerberger F, Wagner M. Listeriosis: a resurgent foodborne infec-
tion. Clin Microbiol Infect 2010; 16: 16–23.
5. Mook P, O’Brien SJ, Gillespie IA. Concurrent conditions and human
listeriosis, England, 1999–2009. Emerg Infect Dis 2011; 17: 38–43.
694 Clinical Microbiology and Infection, Volume 18 Number 7, July 2012 CMI
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, 690–695
6. Rocourt J, Bille J. Foodborne listeriosis. World Health Stat Q 1997; 50:
67–73.
7. Jurado RL, Farley MM, Pereira E et al. Increased risk of meningitis
and bacteremia due to Listeria monocytogenes in patients with human
immunodeficiency virus infection. Clin Infect Dis 1993; 17: 224–227.
8. Pen˜a-Sagredo JL, Herna´ndez MV, Fernandez-Llanio N et al. Listeria
monocytogenes infection in patients with rheumatic diseases on TNF-
alpha antagonist therapy: the Spanish Study Group experience. Clin
Exp Rheumatol 2008; 26: 854–859.
9. Hof H, Nichterlein T, Kretschmar M. Management of listeriosis. Clin
Microbiol Rev 1997; 10: 345–357.
10. Bille J. Listeria and erysipelothrix. In: Murray PR, Baron EJ, Jorgensen
JH, Landry ML, Pfaller MA, eds. Manual of clinical microbiology, 9th
edn. Washington, DC: ASM Press, 2007; 474–484.
11. Clinical and Laboratory Standards Institute (CLSI). Methods for antimi-
crobial dilution and disk susceptibility testing of infrequently isolated or fas-
tidious bacteria; approved guideline. Wayne, PA: CLSI, 2006.
12. Bennion JR, Sorvillo F, Wise ME, Krishna S, Mascola L. Decreasing lis-
teriosis mortality in the United States, 1990–2005. Clin Infect Dis
2008; 47: 867–874.
13. Garrido V, Torroba L, Garcı´a-Jalo´n I, Vitas AI. Surveillance of listerio-
sis in Navarre, Spain, 1995–2005—epidemiological patterns and char-
acterisation of clinical and food isolates. Euro Surveill 2008; 13: pii:
19058.
14. Guevara RE, Mascola L, Sorvillo F. Risk factors for nonperinatal liste-
riosis mortality in Los Angeles County, California, 1992–2004. Clin
Infect Dis 2009; 48: 1507–1515.
15. Fernandez-Sabe N, Cervera C, Lo´pez-Medrano F et al. Risk factors,
clinical features and outcomes of listeriosis in solid-organ transplant
recipients: a matched case–control study. Clin Infect Dis 2009; 49:
1153–1159.
16. Mitja O, Pigrau C, Ruiz I et al. Predictors of mortality and impact on
outcome in listeriosis in a retrospective cohort study. J Antimicrob
Chemother 2009; 64: 416–423.
17. Siegman-Igra Y, Levin R, Weinberger M. Listeria monocytogenes infec-
tion in Israel and review of cases worldwide. Emerg Infect Dis 2002;
8: 305–310.
18. Graham JC, Lanser S, Bignardi G, Pedler S, Hollyoak V. Hospital-
acquired listeriosis. J Hosp Infect 2002; 51: 136–139.
19. Safdar A, Armstrong D. Listeriosis in patients at a comprehensive
cancer center, 1957–1997. Clin Infect Dis 2003; 37: 359–364.
20. Mylonakis E, Hohmann EL, Calderwood SB. Central nervous system
infection with Listeria monocytogenes: 33 years’ experience at a general
hospital and review of 776 episodes from the literature. Medicine (Bal-
timore) 1998; 77: 313–336.
21. Goulet V, Marchetti P. Listeriosis in 225 non-pregnant patients in
1992: clinical aspects and outcome in relation to predisposing condi-
tions. Scand J Infect Dis 1996; 28: 367–374.
22. Gerner-Smidt P, Ethelberg S, Schiellerup P et al. Invasive listeriosis in
Denmark 1994–2003: a review of 299 cases with special emphasis on
risk factors for mortality. Clin Microbiol Infect 2005; 11: 618–624.
23. Safdar A, Armstrong D. Antimicrobial activities against 84 Listeria
monocytogenes isolates from patients with systemic listeriosis at a
comprehensive cancer center (1955–1997). J Clin Microbiol 2003; 41:
483–485.
24. Troxler R, von Graevenitz A, Funke G, Wiedemann B, Stock I. Natu-
ral antibiotic susceptibility of Listeria species: L. grayi, L. innocua, L. iva-
novii, L. monocytogenes, L. seeligeri and L. welshimeri strains. Clin
Microbiol Infect 2000; 6: 525–535.
25. Morvan A, Moubareck C, Leclercq A et al. Antimicrobial resistance
of Listeria monocytogenes strains isolated from humans in France. Anti-
microb Agents Chemother 2010; 54: 2728–2731.
26. Wacker P, Ozsahin H, Groll AH, Gervaix A, Reinhard L, Humbert J.
Trimethoprim-sulfamethoxazole salvage for refractory listeriosis
during maintenance chemotherapy for acute lymphoblastic leukemia.
J Pediatr Hematol Oncol 2000; 22: 340–343.
27. Grant MH, Ravreby H, Lorber B. Cure of Listeria monocytogenes men-
ingitis after early transition to oral therapy. Antimicrob Agents Chemo-
ther 2010; 54: 2276–2277.
28. Merle-Melet M, Dossou-Gbete L, Meyer P et al. Is amoxicillin-cotrim-
oxazole the most appropriate antibiotic regimen for Listeria menin-
goencephalitis? Review of 22 cases and the literature. J Infect 1996;
33: 79–85.
29. Varma JK, Samuel MC, Marcus R et al. Listeria monocytogenes infection
from foods prepared in a commercial establishment: a case–control
study of potential sources of sporadic illness in the United States. Clin
Infect Dis 2007; 44: 521–528.
CMI Ferna´ndez Guerrero et al. Listeriosis 695
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, 690–695
